Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IN-A012 vs Akynzeo Bioequivalence Study
NCT04486157Phase 1Completed
- Sponsor
- HK inno.N Corporation
- Start
- Mar 2021
- Primary completion
- Apr 2021
- Modality
- Prodrugs/Conditional Activator Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of fosnetupitant and palonosetron in chemotherapy-induced nausea and vomiting (CINV) (2 arms), sponsored by HK inno.N Corporation. Primary endpoint: Area Under the Concentration-Time Curve From Time Zero to Time t at 240 hours. Started Mar 2021; status: completed.
02
Drugs
fosnetupitantpalonosetron
03
Conditions
chemotherapy-induced nausea and vomiting (CINV)
Beyond the preview
Go deeper on NCT04486157.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04486157.